Does a cholesterol drug called evolocumab hurt your blood sugar?
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study tested a powerful cholesterol-lowering drug in people with heart disease to see if it made their blood sugar worse or caused diabetes.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 573 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study tested a powerful cholesterol-lowering drug in people with heart disease to see if it made their blood sugar worse or caused diabetes.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 573 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Related Content
Claims (5)
In clinical studies, the rate of side effects from evolocumab was similar to that of a placebo, regardless of whether patients had diabetes or not.
For adults with heart disease who are already taking statins, adding evolocumab injections every two weeks or monthly lowers the risk of serious heart problems like heart attack, stroke, or hospitalization for chest pain by about 13% to 17% over about two years, whether or not they have diabetes.
In people without diabetes, taking evolocumab for about two years does not raise the likelihood of developing diabetes, even in those with prediabetes. The data show no meaningful change in diabetes risk associated with this cholesterol-lowering drug.
In people with prediabetes and heart disease, taking evolocumab for about two years does not increase the risk of developing diabetes, based on measurements of blood sugar levels and diabetes incidence over time.
In people with diabetes, taking the cholesterol-lowering drug evolocumab for about two years does not lead to changes in blood sugar levels compared to a placebo.